Leadership

In this latest Harvard Business School Healthcare Alumni Association Q&A, JT Saunders, Chief Diversity Officer at global consulting firm Korn Ferry, discusses diversity in pharma, as well as what mentors and mentees should be considering in the workplace.

The core building blocks of trust must be operationalized for pharma companies to strengthen their social contract, deliver business value, and improve patients’ quality of life.

The impact on clinical trial staffing would be particularly significant.

Pharm Exec profiles its 2023 Emerging Pharma Leaders.

The 2023 Emerging Pharma Leaders share with the Pharmaceutical Executive editors what makes a good leader, what has made them the proudest in their career, lessons they wish they had known when starting out, and more. (This is the video podcast of the Pharm Exec Podcast episode!)

Winselow Tucker, chief commercial officer, Loxo@Lilly (Eli Lilly’s oncology unit), discusses where to make budget cuts, how to motivate a team, what he wishes he had known earlier in his career, as well as his new role at Loxo@Lilly.

According to the latest State of Revenue survey of c-suite executives, pharma manufacturers are prioritizing digital transformation while struggling with inflation and supply chain disruptions.

There is room to improve what good looks like across the industry.

A discussion with medical leaders on the present and future state of this vital biopharmaceutical function.

Delivering value with enterprise program management.

Pete O'Heeron, founder, chairman, and CEO of FibroBiologics, explains the key principles that biotechnology companies should follow.

Companies should search within to gain talent edge.

Why enabling a shared culture of quality across an organization is key to maintaining pharma’s recent pace of innovation wins—while inspiring new levels of confidence.

Three simple ways to build trust—by reaching outside your comfort zone.

Hiring new employees may not be the answer to the war for talent.

How companies can adapt to today’s fast-changing hiring climate.

Professor Nalebuff discusses the importance of negotiating and understanding what's actually at stake.

There are several strategies life sciences companies can use to benefit from biosimilars.

Key traits needed by leaders looking to grow their organizations in the biosimilars market.

How effective training programs enable ‘next-generation’ patient engagement.

Pharma companies must revise their recruitment strategies in the wake of a skills shortage.

Pfeffer discusses his seven rules for power.

COVID-19 pandemic, the challenging capital-markets climate in biotech, and a more innovative and specialty treatment focus has increased reliance on the finance arm as a key strategic cog.

For industries like pharma, company voices are vital to building trust.